In detail, the loss-of-function mutations of SPOP could prevent ubiquitination-mediated PD-L1 degradation, demonstrating that patients with prostate cancer had a worse prognosis and therapy effect through increasing PD-L1 levels and decreasing tumor-infiltrating lymphocytes [5]. This evidence concerns the gene SPOP and prostate cancer.